Loading clinical trials...

Fecal Microbiota Transplantation in Postoperative Crohn's Disease | Clinical Trials | Clareo Health

RECRUITINGNA

Fecal Microbiota Transplantation in Postoperative Crohn's Disease

NCT04637438•Tampere University Hospital

Summary

This pilot study aims to detect possible trends or signals suggesting efficacy of FMT on prevention of delay of POR, to determine the safety of FMT in post operative CD, and asses if a full randomised controlled trial is feasible in this setting. With microbiota analysis we aim to assess if changes in gut microbiota are related to disease course of CD after operation.

Eligibility

Age

18 - 120 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Over 18 years
•Able to provide written consent
•Stricturing and/or fistulizing Crohn's disease needing ileocecal or ileal resection

Exclusion Criteria

•Pregnancy
•Active infection, abscess or fistula at the time of the first colonoscopy
•Life expectancy \<1 year
•Unable to provide written consent
•Use on antibiotics or probiotics at the time of first colonoscopy

Locations (2)

Tampere University Hospital

Tampere, Finland

Tampere University Hospital

Tampere, Finland

Key Dates

Start Date

May 18, 2021

Primary Completion Date

December 1, 2023

Completion Date

December 1, 2027

Last Updated

October 27, 2022

Enrollment

ESTIMATED participants

Conditions

Crohn Disease

Interventions

Fecal Microbiota Transplantation

OTHER

Placebo

OTHER

Contacts

Elina Jokinen, PhD

CONTACT

+3583311611 elina.jokinen@pshp.fi

Switching to the IL-23 Inhibitor Guselkumab for People With Active IBD Who Previously Used Ustekinumab (SHIFT-IBD)

NCT07245394

Inflammatory Bowel Disease (IBD)Crohn Disease (CD)+2 more

View study

RECRUITING

ALPCO/Calprotectin CLIA Assay: Expected Values of Calprotectin in Healthy Subjects

NCT07089420

IBD (Inflammatory Bowel Disease)IBS - Irritable Bowel Syndrome+2 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: October 27, 2022Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Fecal Microbiota Transplantation in Postoperative Crohn's Disease

Inclusion Criteria

Exclusion Criteria

Switching to the IL-23 Inhibitor Guselkumab for People With Active IBD Who Previously Used Ustekinumab (SHIFT-IBD)

ALPCO/Calprotectin CLIA Assay: Expected Values of Calprotectin in Healthy Subjects

Immunological Characteristics of Preclinical IBD

Impact of Exclusion Diet in Addition to Anti-TNF Therapy in Crohn's Disease and Ulcerative Colitis: a Prospective, Randomized, Double-arm, Open-label Study

Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)

Robotic Inflammatory Bowel Disease Development, Learning and Efficacy Study